Skip to main content

Table 3 Genetic polymorphisms in combination of ERCC1 and XRCC1 and survival of patients

From: Association between polymorphisms in DNA repair genes and survival of non-smoking female patients with lung adenocarcinoma

Stage Combined genotype Patients(%) MST(mon) Log-rank P HR(95%CI)a
all 0 variant 67(26.1) 25.10   1.00
  1 variant allele 100(38.9) 13.07   1.52(1.04-2.22)
  2 variant alleles 58(22.6) 9.27 < 0.001 2.33(1.54-3.50)
  3 variant alleles 26(10.1) 6.30   2.98(1.76-5.04)
  4 variant alleles 6(2.3) 3.87   9.24(3.50-24.44)
I and II 0 variant 26(33.3) 45.80   1.00
  1 variant allele 30(38.5) 22.27   1.98(0.86-4.58)
  2 variant alleles 14(17.9) 11.60 0.145 2.81(1.10-7.13)
  3 variant alleles 6(7.7) --b   1.41(0.26-6.75)
  4 variant alleles 2 (2.6) 17.27   9.05(1.04-78.76)
III and IV 0 variant 41(22.9) 19.10   1.00
  1 variant allele 70(39.1) 11.17   1.54(0.98-2.39)
  2 variant alleles 44(24.6) 8.93 < 0.001 2.29(1.44-3.66)
  3 variant alleles 20(11.2) 5.83   3.69(2.06-6.62)
  4 variant alleles 4(2.2) 3.63   18.50(5.68-60.23)
  1. Abbreviation: MST, median survival time; HR, hazard ratio; CI, confidence interval.
  2. aHR adjusted for age, stage, surgical operation and chemotherapy or radiotherapy.
  3. bMST for this genotype could not be calculated.